

Tel: (614) 722-5477 / (800) 934-6575

NationwideChildrens.org/Lab

Oncology Genetic Test Requisition Form

Institute for Genomic Medicine (IGM) Clinical Laboratory Tel: (614) 722-5321 / Fax: (614) 722-5471

Ship Samples to: Nationwide Children's Laboratory Services

700 Children's Drive, Room C1955 Columbus, OH 43205 U.S.A.

PATIENT INFOR	MATION (Please Prin	nt or Pl	lace IE	D Label)				
Last Name				irst Name				MI
Date of Birth (DOB)	Sex Assigned at Birth Male Female Unkno		der Ident	ity	SSN		Patient	ID #/ MRN
Street Address		l .	С	ity		State		Zip
ORDERING PHY	SICIAN INFORMATION	ON (P	lease	Print)				
Ordering Physician Na				REQUIRED)	Fax	(REQUIRE	D)	NPI #
Attending Physician Ir Attending Physician Na	nformation - REQUIRED if O		Physici Phone	an is a Trai	nee (e.g. l		ellow)	NPI#
Institution / Practice / F	acility Name	ı						
Street Address				City		State		Zip/Postal Code
Physician Email (REQL	JIRED if sending from outsid	de U.S.A	. .)			Country (it	f not U.S	.A.)
Ordering Physican Sig	nature					Date		
ADDITIONAL RE	PORT TO (Please Pr	rint)						
Name	□ Lab □ Other	,	P	hone		Fax		
	AL DIAGNOSIS /SPEC	CIALI	NSTR	UCTION	S			
ICD-10 Codes (REQUII								Age of Onset
Special Instructions /	Notes							
SAMPLE INFOR	MATION (Please List /	All Sar	nples	Being Su	ıbmitted	with This	Form)	
Please check sample i	equirements and exclusion	ns for ea	ch test	on website	e <u>Nationw</u>	ridechildrer	s.org/L	ab.
1 · · · · · · · · · · · · · · · · · · ·	nust be labeled with the name			•			-	sufficiently labeled
	gned specimen identification w					-	_	
	e consumed as needed to com ples are NOT ACCEPTED.	piete tne	e reques	tea testing w	nich may r	esuit in depie	etion of si	ubmitted samples.
	ood samples: Collect 4 mL of bo	ne marro	ow or inv	olved blood s	ample into	EDTA tube. S	hip overni	ight at room temperature
	in the laboratory within 48 hou							
	scrolls must be accompanied b	•	•			•		
	umor section. Fresh/frozen tiss				oratory wi			
Tumor / Involved Sa ☐ Bone marrow	ample: Sample contains _ ☐ Involved peripheral b			blasts esh tissue		Collection	on Date	Sample Time Point: ☐ Diagnosis
☐ Snap-frozen tissue				PE tissue bl	ock			☐ Relapse
•	s <u>and</u> consecutively cut H&E		□ Ot			Time		□ Post-Treatment □ Day
Normal Sample: N	ormal sample must contain	0% tun	nor/blas	ts		Collection	on Date	Sample Time Point:
☐ Bone marrow	☐ Peripheral blood			esh tissue	_			☐ Diagnosis
☐ Snap-frozen tissue				PE tissue bl		Time		☐ Relapse
☐ Other	s <u>and</u> consecutively cut H&E 	siide	⊔ Un	involved pe	riprierai bio	ou		□ Post-Treatment Day
REQUIRED: A copy of include a preliminary	f the <u>Pathology Report</u> is rec report with the sample subr	quired f	or each	submitted en fax the fi	tumor sar nalized re	nple – if the port to 614-	report i: 722-5471	s not finalized, I, once available.

ailure to provide a finalized pathology report can result in a delayed test processing and/or result reporting.



Tel: (800) 934-6575 / NationwideChildrens.org/Lab

Patient Name (or place patient ID label)
Last, First
DOB or MRN

BILLING INFORMATION *Insurance Bill ONLY available if patient was NOT an inpatient at time of collection

- Insurance bill option is available for patients/insurance plans within the state of Ohio. For insurance bill, please attach the front and back copy of the patient's insurance card and complete the "Insurance Bill" section below
- For out-of-Ohio patients/insurance plans, institutional bill option is preferred. We **<u>DO NOT</u>** have contracts with most insurance plans outside of Ohio
- For <u>INTERNATIONAL</u> samples referred from outside the U.S.A. or Canada, we only accept institutional bill. Pre-payment or agreement of payment must be made <u>PRIOR TO</u> sending the sample. Payment can be made by wire transfer or by credit card. To arrange payment, please email <u>Laboratory Billing@NationwideChildrens.org</u>
- We **DO NOT** offer Self-pay option at this time

	aboratory Client Services for r IE Billing method below. Bill		ust be completed to			D. D. ()
■ INSTITUTIO	NAL/CLIENT BILL (Ple	ease Print)	INSURANC Please Attach a			y of Insurance Card
Billing Contact Name	:		Legal Guardian Las	t Name:		
Phone	Fax		Legal Guardian Fire	st Name, MI		
Email Address (Requ	ired)		Legal Guardian DO	В	Legal Gua	ardian SSN
Institution / Hospital /	Laboratory Name		Relationship to Pat		Parent	□ Other
Client Account No (Please contact labor are unsure of your ac	atorybilling@nationwidechild	rens.org if you	Subscriber Last Nar	ne		
lare unsure or your ac	count number)		Subscriber First Na	me, MI		
Street Address			Subscriber DOB			
City			Subscriber SSN			
State / Province			Policy #		Group #	
Zip Code			Insurance Compan	y Name	1	
Country			Insurance Address			
	y to sending institution via: per Above Email address		City	State		Zip
Ullei Fax/Elliali			Secondary Insuran	ce Company I	Name	
Other Information:		1				
PATIENT CONS	ENT FOR INSURANCE	BILL				
	Nationwide Children's Hospi I understand that I am respo					

Patient Signature: X



Patient Name (or place patient ID label)	
Last, First	
DOB or MRN	

	<u>:hildrens.org/Lab</u>	
*Internal pathology review by Nationwide Children's	s pathologistwill be performed	d on submitted samples to assess for tumor/blast content.
HEMATOLOGIC CANCER		
☐ Hematologic Cancer Fusion Analy		
Identifies gene fusions for 148 genes (see *At least 10% blasts must be present in the		
*At least 25% blasts/tumor must be prese (based on internal pathology review). Sam	nt in the FFPE tissue block	s or scrolls.
SOLID TUMOR	ipie acquisition FRIOR TOT	eceiving treatment is strongly preferred.
 □ Solid Tumor Fusion Analysis by N 	IGS (test code: TUMFUSN	1
Identifies gene fusions for 151 genes (see	website for list of all gene p	eartners).
* <u>At least 10% tumor</u> must be present in the * <u>At least 25% tumor</u> must be present in the		
(based on internal pathology review). Sam		
CNS / BRAIN TUMOR		
 CNS Tumor Classification by Meth 		
* <u>At least 60% tumor</u> must be present in the Snap-frozen tissue is Preferred	ne submitted sample (based	on internal pathology review).
MEDULLOBLASTOMA		
☐ MYCN (N-MYC) and MYC (C-MYC)		
* <u>At least 10% tumor (30% if bone marrow</u> FFPE unstained slides are Preferred ; pleas		omitted sample (based on internal pathology review). thick) <u>AND</u> consecutively cut H&E slide.
ALVEOLAR RHABDOMYOSARCO	MA	
☐ FOXO1 (FKHR) Rearrangement De	_	
Identifies PAX3-FOXO1 and PAX7-FOXO	11 fucione [t/2·13]/a35·a1/	l) and t(1:13)(n36:d14)]
If FOXO1 rearrangement is identified, refl * <u>At least 10% tumor</u> must be present	ex to PAX3 will occur first. If th in submitted sample (based	at is negative, reflex to PAX7 will then occur. on internal pathology review).
If FOXO1 rearrangement is identified, reflo * <u>At least 10% tumor</u> must be present FFPE unstained slides are Preferred ;	ex to PAX3 will occur first. If th in submitted sample (based	at is negative, reflex to PAX7 will then occur.
If FOXO1 rearrangement is identified, reflier *At least 10% tumor must be present FFPE unstained slides are Preferred; SARCOMA	ex to PAX3 will occur first. If th in submitted sample (based please submit 6 slides (3 mid	at is negative, reflex to PAX7 will then occur. on internal pathology review). cron thick) <u>AND</u> consecutively cut H&E slide
If FOXO1 rearrangement is identified, refli- *At least 10% tumor must be present FFPE unstained slides are Preferred; p SARCOMA Soft Tissue Sarcoma Tumor Analysis	ex to PAX3 will occur first. If th in submitted sample (based please submit 6 slides (3 mid	at is negative, reflex to PAX7 will then occur. on internal pathology review). cron thick) AND consecutively cut H&E slide RTPCR] FFPE Sample is NOT
If FOXO1 rearrangement is identified, reflier *At least 10% tumor must be present FFPE unstained slides are Preferred; SARCOMA	ex to PAX3 will occur first. If the in submitted sample (based please submit 6 slides (3 mids) by RT-PCR [test code:	at is negative, reflex to PAX7 will then occur. on internal pathology review). cron thick) AND consecutively cut H&E slide
If FOXO1 rearrangement is identified, refli- *At least 10% tumor must be present FFPE unstained slides are Preferred; SARCOMA Soft Tissue Sarcoma Tumor Analysis Snap-frozen tumor tissue is Preferred	ex to PAX3 will occur first. If the in submitted sample (based please submit 6 slides (3 mids by RT-PCR [test code:	at is negative, reflex to PAX7 will then occur. I on internal pathology review). Coron thick) AND consecutively cut H&E slide [RTPCR] FFPE Sample is NOT ACCEPTED for This Test
If FOXO1 rearrangement is identified, reflective to the second of the se	ex to PAX3 will occur first. If the in submitted sample (based please submit 6 slides (3 mid by RT-PCR [test code: Dw) wing selected sarcoma is EWS-ERG fusions [t(11;2)]	at is negative, reflex to PAX7 will then occur. If on internal pathology review). It on thick) AND consecutively cut H&E slide RTPCR] FFPE Sample is NOT ACCEPTED for This Test Itypes: Itypes: Itypes:
If FOXO1 rearrangement is identified, reflective to the second of the se	ex to PAX3 will occur first. If the in submitted sample (based please submit 6 slides (3 mids by RT-PCR [test code: 0w) wing selected sarcoma is EWS-ERG fusions [t(11;2) PAX3-FOXO1 and PAX7-F	at is negative, reflex to PAX7 will then occur. on internal pathology review). cron thick) AND consecutively cut H&E slide RTPCR] FFPE Sample is NOT ACCEPTED for This Test types: 2)(q24;q12) and t(21;22)(q22;q12)] FOXO1 fusions [t(2;13)(q35;q14) and t(1;13)(p36;q14)]
If FOXO1 rearrangement is identified, reflection *At least 10% tumor must be present FFPE unstained slides are Preferred; part SARCOMA Soft Tissue Sarcoma Tumor Analysis Snap-frozen tumor tissue is Preferred Full Panel (includes all listed below or Specific RT- PCR for the follow Ewing sarcoma EWS-FLI-1 and Alveolar rhabdomyosarcoma Synovial sarcoma SyT-SSX1/S	ex to PAX3 will occur first. If the in submitted sample (based please submit 6 slides (3 mid by RT-PCR [test code: by RT-PCR [test code: by W) wing selected sarcoma if EWS-ERG fusions [t(11;2) PAX3-FOXO1 and PAX7-F SSX2 fusion [t(X;18)(p11.2;0)	at is negative, reflex to PAX7 will then occur. If on internal pathology review). In original pathology review revi
If FOXO1 rearrangement is identified, reflexAt least 10% tumor must be present FFPE unstained slides are Preferred; particles and SARCOMA Soft Tissue Sarcoma Tumor Analysis Snap-frozen tumor tissue is Preferred Full Panel (includes all listed below or Specific RT- PCR for the follow Ewing sarcoma EWS-FLI-1 and Alveolar rhabdomyosarcoma Synovial sarcoma SYT-SSX1/SD Desmoplastic small round cele	ex to PAX3 will occur first. If the in submitted sample (based please submit 6 slides (3 mid by RT-PCR [test code: by RT-PCR [test code: by RT-PCR] Wing selected sarcoma if EWS-ERG fusions [t(11;2 PAX3-FOXO1 and PAX7-FOSX2 fusion [t(X;18)(p11.2;6 ll tumor EWS-WT1 fusion submitted for the interval of	at is negative, reflex to PAX7 will then occur. In on internal pathology review). In original pathology review revie
If FOXO1 rearrangement is identified, reflex *At least 10% tumor must be present FFPE unstained slides are Preferred; SARCOMA Soft Tissue Sarcoma Tumor Analysis Snap-frozen tumor tissue is Preferred Full Panel (includes all listed below or Specific RT- PCR for the follow Ewing sarcoma EWS-FLI-1 and Alveolar rhabdomyosarcoma Synovial sarcoma SYT-SSX1/SD Desmoplastic small round cellow Congenital fibrosarcoma/cellu	ex to PAX3 will occur first. If the in submitted sample (based please submit 6 slides (3 mid ple	at is negative, reflex to PAX7 will then occur. If on internal pathology review). In original pathology review revi
If FOXO1 rearrangement is identified, reflexAt least 10% tumor must be present FFPE unstained slides are Preferred; particles and SARCOMA Soft Tissue Sarcoma Tumor Analysis Snap-frozen tumor tissue is Preferred Full Panel (includes all listed below or Specific RT- PCR for the follow Ewing sarcoma EWS-FLI-1 and Alveolar rhabdomyosarcoma Synovial sarcoma SYT-SSX1/SD Desmoplastic small round cele	ex to PAX3 will occur first. If the in submitted sample (based please submit 6 slides (3 mid ple	at is negative, reflex to PAX7 will then occur. In on internal pathology review). In order thick) AND consecutively cut H&E slide RTPCR] FFPE Sample is NOT ACCEPTED for This Test types: (2)(q24;q12) and t(21;22)(q22;q12)] FOXO1 fusions [t(2;13)(q35;q14) and t(1;13)(p36;q14)] (q11.2)] (p11.2)] (p11.2)] (p12.2)(p13;q12)] (p13.2) (p13.2)[(p1
If FOXO1 rearrangement is identified, reflexAt least 10% tumor must be present FFPE unstained slides are Preferred; page 54 SARCOMA Soft Tissue Sarcoma Tumor Analysis Snap-frozen tumor tissue is Preferred Full Panel (includes all listed below or Specific RT- PCR for the follow Ewing sarcoma EWS-FLI-1 and Alveolar rhabdomyosarcoma Synovial sarcoma SYT-SSX1/SD Desmoplastic small round cellow Congenital fibrosarcoma/cellow EWSR1 FISH Tumor Analysis (test of Identifies if EWSR1 gene is rearranged but *At least 10% tumor must be present in substance in substanc	ex to PAX3 will occur first. If the in submitted sample (based please submit 6 slides (3 mid please	at is negative, reflex to PAX7 will then occur. In on internal pathology review). In original pathology review). In original pathology review). In original pathology review). In original pathology review). FFPE Sample is NOT ACCEPTED for This Test ACCEPTED for This Test Itypes: Ityp
If FOXO1 rearrangement is identified, reflex *At least 10% tumor must be present FFPE unstained slides are Preferred; particles and FFPE unstained slides are Preferred; particles are preferred; particles are preferred. SARCOMA Soft Tissue Sarcoma Tumor Analysis Snap-frozen tumor tissue is Preferred. Full Panel (includes all listed below or Specific RT- PCR for the follow Ewing sarcoma EWS-FLI-1 and Alveolar rhabdomyosarcoma. Alveolar rhabdomyosarcoma. Synovial sarcoma SYT-SSX1/S. Desmoplastic small round cells Congenital fibrosarcoma/cells. EWSR1 FISH Tumor Analysis (test condensities if EWSR1 gene is rearranged but *At least 10% tumor must be present in sub FFPE unstained slides are Preferred; please	ex to PAX3 will occur first. If the in submitted sample (based please submit 6 slides (3 mid please	at is negative, reflex to PAX7 will then occur. In on internal pathology review). In original pathology review). In original pathology review). In original pathology review). In original pathology review). FFPE Sample is NOT ACCEPTED for This Test ACCEPTED for This Test Itypes: Ityp
If FOXO1 rearrangement is identified, reflexAt least 10% tumor must be present FFPE unstained slides are Preferred; page 5 SARCOMA Soft Tissue Sarcoma Tumor Analysis Snap-frozen tumor tissue is Preferred Full Panel (includes all listed below or Specific RT- PCR for the follow Ewing sarcoma EWS-FLI-1 and Alveolar rhabdomyosarcoma Synovial sarcoma SYT-SSX1/S Desmoplastic small round cell Congenital fibrosarcoma/cellum EWSR1 FISH Tumor Analysis (test of Identifies if EWSR1 gene is rearranged but *At least 10% tumor must be present in sub FFPE unstained slides are Preferred; please WILMS TUMOR	ex to PAX3 will occur first. If the in submitted sample (based please submit 6 slides (3 mids) by RT-PCR [test code: by RT-PCR [test code: by RT-PCR] [test code	at is negative, reflex to PAX7 will then occur. In on internal pathology review). In order thick) AND consecutively cut H&E slide RTPCR] FFPE Sample is NOT ACCEPTED for This Test ACCEPTED for This Test Express:
If FOXO1 rearrangement is identified, reflexAt least 10% tumor must be present FFPE unstained slides are Preferred; page 5 SARCOMA Soft Tissue Sarcoma Tumor Analysis Snap-frozen tumor tissue is Preferred Full Panel (includes all listed below or Specific RT- PCR for the follow Ewing sarcoma EWS-FLI-1 and Alveolar rhabdomyosarcoma Synovial sarcoma SYT-SSX1/S Desmoplastic small round cell Congenital fibrosarcoma/cellum EWSR1 FISH Tumor Analysis (test of Identifies if EWSR1 gene is rearranged but *At least 10% tumor must be present in sub FFPE unstained slides are Preferred; please WILMS TUMOR	ex to PAX3 will occur first. If the in submitted sample (based please submit 6 slides (3 mids) by RT-PCR [test code: by RT-PCR [test code: by RT-PCR] [test code: TONCR] [test code: TONCR] [test code: TONCR]	at is negative, reflex to PAX7 will then occur. In on internal pathology review). In order thick) AND consecutively cut H&E slide RTPCR] FFPE Sample is NOT ACCEPTED for This Test ACCEPTED for This Test ACCEPTED for This Test Express: 12)(q24;q12) and t(21;22)(q22;q12)] 150X01 fusions [t(2;13)(q35;q14) and t(1;13)(p36;q14)] 1611.2)] 17 part [t(11;22)(p13;q12)] 18 part fusion partner. 19 part fusion partner. 19 part fusion partner. 10 part fusion partner. 10 part fusion partner. 11 part fusion partner. 12 part fusion partner. 13 part fusion partner. 14 part fusion partner. 15 part fusion partner. 16 part fusion partner. 17 part fusion partner. 18 part fusion partner. 19 part fusion partner. 10 part fusion partner. 10 part fusion partner. 11 part fusion partner. 12 part fusion partner. 13 part fusion partner. 14 part fusion partner. 15 part fusion partner. 16 part fusion partner. 17 part fusion partner. 18 part fusion partner. 19 part fusion partner. 19 part fusion partner. 10 part fusion partner. 10 part fusion partner. 10 part fusion partner. 11 part fusion partner. 12 part fusion partner. 13 part fusion partner. 14 part fusion partner. 15 part fusion partner. 16 part fusion partner. 17 part fusion partner. 18 part fusion partner. 19 part fusion partner. 19 part fusion partner. 10 part fusion partner. 10 part fusion partner. 10 part fusion partner. 11 part fusion partner. 12 part fusion partner. 13 part fusion partner. 14 part fusion partner. 15 part fusion partner. 16 part fusion partner. 17 part fusion partner. 18 part fusion partner. 19 part fusion partner. 19 part fusion partner. 10 part fusion partner. 10 part fusion partner. 10 partner. 11 partner. 12 partner. 13 partner. 14 partner. 15 partner. 16 partner. 17 partner. 18 partner. 18 partner. 19 partner. 19 partner. 10 partner. 10 partner. 10 partner. 10 partner. 10 partner. 11 partner. 12 partner. 13 partner. 14 partner. 15 partner. 16 partner. 17 partner. 18 partner.



Tel: (800) 934-6575 / NationwideChildrens.org/Lab

Patient Name (or place patient ID label)				
Last, First				
DOB or MRN				

*Internal pathology review by Nationwide Children's pathologist will be performed on submitted samples to assess for tumor/blast content.

NEUROBLASTOMA	
☐ Targeted Oncology Microarray Analysis [test code: TONCMA] — Id *At least 40% tumor must be present in the submitted sample (based on international sample) Snap-frozen tissue is Preferred Targeted Oncology Microarray Analysis [test code: TONCMA] — Id *At least 40% tumor must be present in the submitted sample (based on international sample) Targeted Oncology Microarray Analysis [test code: TONCMA] — Id *At least 40% tumor must be present in the submitted sample (based on international sample) Targeted Oncology Microarray Analysis [test code: TONCMA] — Id *At least 40% tumor must be present in the submitted sample (based on international sample) Targeted Oncology Microarray Analysis [test code: TONCMA] — Id **At least 40% tumor must be present in the submitted sample (based on international sample) Targeted Oncology Microarray Analysis [test code: TONCMA] — Id **At least 40% tumor must be present in the submitted sample (based on international sample) Targeted Oncology Microarray Analysis [test code: TONCMA] — Id **Total Sample (based on international sample) Targeted Oncology Microarray Analysis [test code: TONCMA] — Id **Total Sample (based on international sample) Targeted Oncology Microarray Analysis [test code: TONCMA] — Id **Total Sample (based on international sample) Targeted Oncology Microarray Analysis [test code: TONCMA] — Id **Total Sample (based on international sample) Targeted Oncology Microarray Analysis [test code: TONCMA] — Id **Total Sample (based on international sample) Targeted Oncology Microarray Analysis [test code: Toncology Microarray Analysis [t	
MYCN (N-MYC) Amplification by FISH [test code: FISHTUMOR] *At least 10% tumor (30% if bone marrow) must be present in the submitted s FFPE unstained slides are Preferred; please submit 6 slides (3 micron thick) Al	
☐ ALK Amplification by FISH [test code: FISHALK] *At least 10% tumor (30% tumor for bone marrow) must be present in submit	itted sample (based on internal pathology review).
□ NGS Neuroblastoma Panel [test code: NGSNBL] *At least 20% tumor must be present in submitted sample (based on internal p.	pathology review).
☐ DNA Ploidy Analysis [test code: DNAP] Slides are NOT ACCEPT	TED for This Test
CUSTOM CONFIRMATION TESTS TARGETED TUMOR VARIANT ANALYSIS - Confirmatory Test Targeted Tumor Variant Analysis [test code: TTVA] A copy of the previous research/clinical tumor sequencing result is REQUIRE *At least 50% blasts must be present in hematologic cancer samples, and	
*At least 40% tumor must be present in solid tumor samples (based on internal Submission of a normal sample (containing 0% tumor) is recommended but not	
Genome Build: ☐ GRCh37 (hg19) ☐ GRCh38	
1. Gene:Variant (c./p.):	Transcript (NM#):
2. Gene: Variant (c./p.):	Transcript (NM#):
3. Gene:Variant (c./p.):	Transcript (NM#):
Previous sequencing performed at (Lab Name):	
Previous tumor sequencing performed as a Clinical testing	☐ Research testing
TARGETED TUMOR FUSION ANALYSIS - Confirmatory Test f	for a Known Gene Fusion
□ RT-PCR Fusion Confirmation [test code: FUSNCON] A copy of the previous research/clinical tumor fusion result is REQUIRED. *At least 10% tumor must be present in the submitted hematologic or solid tumor sample (based on internal pathology review) Genome Build: □ GRCh37 (hg19) □ GRCh38	This Test is <u>NOT</u> for MRD Detection
Test for a fusion between these 2 genes:	
• 5' Fusion Gene Partner: Transcript (NM#):	
Breakpoint: Exon: Genomic Coordinate:	
• 3' Fusion Gene Partner: Transcript (NM#):	
Breakpoint: Exon: Genomic Coordinate:	
Test for additional gene fusions (specify):	
Previous fusion analysis performed at (Lab Name): Previous tumor fusion analysis performed as a: Clinical testing	



Tel: (800) 934-6575 / NationwideChildrens.org/Lab

Patient Name (or place patient ID label)			
Last, First			
DOB or MRN			

Please check sample requirements and exclusions for each test on website Nationwidechildrens.org/Lab.

Ship Samples and Completed Test Requisition Form to:

Nationwide Children's Hospital Laboratory 700 Children's Drive, Room C1955 Columbus, OH 43205 U.S.A.

- Ship samples via Overnight Courier. Samples must arrive the laboratory within 48 hours. Saturday deliveries accepted. Please check "Saturday Delivery" on shipment label.
- For questions regarding testing, specimen requirements or transport, please call IGM Clinical Laboratory at (614) 722-5321 or Lab Client Services at (800) 934-6575.

•	urn Request: returned after testing is complete	te if there is remaining sample. Provide return details below:
Ship Back to: Name: _		Phone:
Address: _		
-		
-		